BIVI (BioVie) ROE % Adjusted to Book Value: -177.79% (As of Mar. 2026)


BIVI BioVie Inc BIVI
34 GF Score
Price $1.94
! 1 Warning Sign
View Full Analysis

What is BioVie ROE % Adjusted to Book Value?

BioVie BIVI -3.00% 34 ROE % Adjusted to Book Value is -177.79% as of Mar. 2026. GuruFocus rates BIVI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

BioVie's ROE % for the quarter that ended in Mar. 2026 was -120.90%. BioVie's PB Ratio for the quarter that ended in Mar. 2026 was 0.68. BioVie's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -177.79%.

BioVie ROE % Adjusted to Book Value Related Terms

BioVie ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BioVie's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVie ROE % Adjusted to Book Value Chart

BioVie Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -60.61 -51.68 -130.17 -109.29

BioVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.75 -73.51 -162.54 -244.18 -177.79

BIVI vs CYCN, LNAI, CTXR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BioVie's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVie ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BioVie's ROE % Adjusted to Book Value falls into.


BIVI
34GF Score
BioVie Inc BIVI
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVie ROE % Adjusted to Book Value Calculation

BioVie's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-101.64% / 0.93
=-109.29%

BioVie's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-120.90% / 0.68
=-177.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -177.79% mean?
BioVie (BIVI) has a ROE % Adjusted to Book Value of -177.79% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioVie and its competitors.
Is BioVie's ROE % Adjusted to Book Value too high?
BioVie's current ROE % Adjusted to Book Value is -177.79%. Overall, BioVie has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BioVie's ROE % Adjusted to Book Value compare to CYCN and LNAI?
BioVie's ROE % Adjusted to Book Value of -177.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioVie and its competitors. BioVie's current ROE % Adjusted to Book Value is -177.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVie stock overvalued right now?
BioVie (BIVI) has a current ROE % Adjusted to Book Value of -177.79%. The current ROE % Adjusted to Book Value is -177.79%. BioVie's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioVie (BIVI), the current ROE % Adjusted to Book Value is -177.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVie Business Description

Address 680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
34GF Score

Get the complete analysis for BIVI

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.94
Price